With so many shares to choose from on the Australian share market, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.
Three top ASX shares that leading brokers have named as buys this week are listed below. Here's why they are bullish on them:
Image Source: Getty Images
Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH)
According to a note out of Macquarie, its analysts have retained their outperform rating on this medical device company's shares with an improved price target of NZ$39.30 (A$36.51). This follows the release of Fisher & Paykel Healthcare's full year results last week, which beat both on the top line and with margins. And while the company's FY 2026 guidance fell short of expectations, the broker remains positive. Especially given that despite tariff headwinds, Fisher & Paykel Healthcare still expects to achieve its 65% gross margin target by FY 2028. This is ahead of what Macquarie was forecasting. Outside this, Macquarie sees the medium to longer-term outlook as favourable, supported by uptake of new app consumables, OSA patient growth, and increased utilisation from changing clinical practices. The Fisher & Paykel Healthcare share price is trading at $34.55 today.
Integral Diagnostics Ltd (ASX: IDX)
A note out of Bell Potter reveals that its analysts have retained their buy rating on this diagnostic imaging services provider's shares with an improved price target of $3.65. The broker is expecting Integral Diagnostics to deliver adjusted annual revenue growth of 34.4% to $631.2 million in FY 2025. Whereas adjusted operating EBITDA is expected to grow 35.7% to $124.2 million. The good news is that Bell Potter then expects this strong form to continue. It thinks the company is emerging with several tailwinds that could support double-digit earnings growth and ultimately a re-rating of its valuation. The Integral Diagnostics share price is fetching $2.45 at the time of writing.
Lynas Rare Earths Ltd (ASX: LYC)
Analysts at Morgan Stanley have retained their overweight rating and $10.00 price target on this rare earths producer's shares. According to the note, the broker is becoming increasingly positive on the company due to its potential to increase production thanks to the new Kalgoorlie facility. This bodes well for Lynas given its position as one of only two global rare earth supply producers outside of China. The Lynas share price is trading at $8.14 this afternoon.
